Other
Gross Unrealized Gains
Regeneron Pharmaceuticals Gross Unrealized Gains decreased by 58.5% to $40.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 28.2%, from $57.00M to $40.90M. Over 5 years (FY 2020 to FY 2025), Gross Unrealized Gains shows an upward trend with a 19.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ4 2017
Last reportedQ1 2026Apr 29, 2026
How to read this metric
An increase indicates favorable market conditions for the fixed-income portfolio, potentially boosting book value.
Detailed definition
The total amount of unrealized gains on debt securities classified as available-for-sale that have not yet been recogniz...
Peer comparison
Standard metric for insurance companies holding large bond portfolios.
Metric ID:
other_available_for_sale_debt_securities_accumulated_gro_8d5dbcHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $25.80M | $21.00M | $10.80M | $1.30M | $100.00K | $100.00K | $900.00K | $10.60M | $1.50M | $900.00K | $13.70M | $7.00M | $4.10M | $100.80M | $30.10M | $57.00M | $77.70M | $93.20M | $98.50M | $40.90M |
| QoQ Change | — | -18.6% | -48.6% | -88.0% | -92.3% | +0.0% | +800.0% | >999% | -85.8% | -40.0% | >999% | -48.9% | -41.4% | >999% | -70.1% | +89.4% | +36.3% | +19.9% | +5.7% | -58.5% |
| YoY Change | — | — | — | — | -99.6% | -99.5% | -91.7% | +715.4% | >999% | +800.0% | >999% | -34.0% | +173.3% | >999% | +119.7% | +714.3% | >999% | -7.5% | +227.2% | -28.2% |
Range$100.00K – $100.80M
CAGR+10.2%
Avg YoY Growth>999%
Median YoY Growth+200.3%
Gross Unrealized Gains at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's gross unrealized gains?
- Regeneron Pharmaceuticals (REGN) reported gross unrealized gains of $40.90M in Q1 2026.
- How has Regeneron Pharmaceuticals's gross unrealized gains changed year-over-year?
- Regeneron Pharmaceuticals's gross unrealized gains decreased by 28.2% year-over-year, from $57.00M to $40.90M.
- What is the long-term trend for Regeneron Pharmaceuticals's gross unrealized gains?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's gross unrealized gains has grown at a 19.7% compound annual growth rate (CAGR), from $40.10M to $98.50M.
- What does gross unrealized gains mean?
- The total paper profit on debt investments that have not been sold yet.